Download this white paper to learn more.
Precision medicine is reshaping the landscape of clinical development, offering more advanced strategies to align therapies with individual biological variability.
Recent research shows that drug targets supported by genetics are 2.6x more likely to succeed in clinical development. In 2024, 38% of FDA approvals were personalized medicines, reflecting how precision strategies are driving real-world adoption. Organizations with access to effective operational frameworks, internally or via partners, can gain efficiency through de-risk development, and support more targeted, impactful therapies.
This white paper explores how pharmacogenomics and biomarker-guided approaches can be successfully integrated into large-scale trials and real-world settings, covering topics such as:
- Where precision medicine makes an impact on drug development
- Practical models for implementation across the lifecycle
- How to balance the benefits and costs of precision medicine
- Case studies of successful precision medicine deployments
- The path to broader adoption of the model
Offered Free by: Seriant
See All Resources from: Seriant
